pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 21·1 min read
save

Proposed OMB Rule Threatens NIH Grant Independence, Experts Warn

Jul 21, 2026·read at STAT ↗RegulatoryNegative

The Office of Management and Budget has issued a proposed rule that would require political appointees to review NIH research grants and certify that the projects "demonstrably advance the President's policy priorities" and do not support "anti-American values."

Under the draft language, a grant could be terminated if it is deemed no longer to serve the "national interest," effectively giving the administration the power to end funding that does not align with the president's preferences. The comment period closed on July 13, and the agency plans to finalize the rule by the end of August.

Critics argue that turning grant decisions into a political process would erode merit-based funding, limit scientific freedom, and push talented researchers away from basic science, possibly even out of the United States.

The proposal has sparked concern among scholars and policymakers who warn that such a shift could weaken the NIH's ability to manage research risk and maintain its role as a neutral steward of federal science funding.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: How a controversial rule could hurt the NIH’s ability to manage risk”

read at STAT ↗
1,171 words · retrieved Jul 21
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
National Institutes of Health
drugs
Bio TObesityTestimVogelxotestosterone
topics
Obesity

related stories

  • Jul 23Opinion: New billing codes likely to raise maternity care costsSTAT
  • Jul 21Opinion: Science and the public are learning the wrong lessons from CovidSTAT
  • Jul 20Opinion: My husband’s suicide shows there’s something very wrong with the U.S. insurance industrySTAT
  • Jul 20STAT+: Telemedicine company touted by Novo Nordisk stressed profits over patient safety, ex-workers saySTAT
  • Jul 20Opinion: It’s time to treat pandemics as threats to national securitySTAT